PAI Holdings, LLC. dba Pharmaceutical Associates Inc FDA Recalls

4 recalls on file across drugs, 0 of them Class I and 0 still open. This firm is not matched to a listed company.

Newest first

Class I is the FDA's most serious grade: a reasonable probability of serious harm or death.

Product	Reason	Class	Initiated
Guaifenesin and Codeine Phosphate Oral Solution USP, 100mg/10 mg per 5 mL, 16 fl oz (473 ml) bottles, PAI PharmaceuticalClass IIIJan 7, 2025Superpotent; sodium benzoate preservative	Superpotent; sodium benzoate preservative	Class IIIDrugs	Jan 7, 2025
Nystatin Oral Suspension, USP 100,000 units per mL, Cherry/Peppermint Flavor, Rx ONLY, packaged in a) 16 fl oz (473 mL)Class IIJul 29, 2021Lack of CGMP: This recall is being carried out due to potent	Lack of CGMP: This recall is being carried out due to potential for carry over of Senna Syrup.	Class IIDrugs	Jul 29, 2021
Ethosuximide Oral Solution USP 250 mg/5 mL, 16 fl oz (473 mL), Rx ONLY, Pharmaceutical Associates, Inc. Greenville, SC Class IIJul 29, 2021Lack of CGMP: This recall is being carried out due to potent	Lack of CGMP: This recall is being carried out due to potential for carry over of Senna Syrup.	Class IIDrugs	Jul 29, 2021
Cimetidine Hydrochloride Oral Solution 300 mg/5 mL, 8 fl oz (237 mL) Rx ONLY, Pharmaceutical Associates, Inc. GreenvillClass IIJul 29, 2021Lack of CGMP: This recall is being carried out due to potent	Lack of CGMP: This recall is being carried out due to potential for carry over of Senna Syrup.	Class IIDrugs	Jul 29, 2021